Expressing Recombinant Receptor Patents (Class 435/361)
-
Publication number: 20120058918Abstract: Disclosed herein are cells and cell lines that stably express CFTR and methods for using those cells and cell lines. The invention also includes techniques for creating these cells and cell lines. The cells and cell lines of this invention are physiologically relevant. They are highly sensitive and provide consistent and reliable results in cell-based assays.Type: ApplicationFiled: February 1, 2010Publication date: March 8, 2012Applicant: CHROMOCELL CORPORATIONInventors: Kambiz Shekdar, Jessica Langer, Srinivasan P. Venkatachalan, Dennis J. Sawchuk
-
Publication number: 20120053321Abstract: Novel methods are disclosed for forming a heterodimeric receptor complex with IL-28R and CRF2-4. The methods may be used for detecting and treating viral infections in in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: ApplicationFiled: October 4, 2011Publication date: March 1, 2012Inventors: Wenfeng Xu, Stacy Schlutsmeyer, Cameron S. Brandt, Wayne R. Kindsvogel, Katherine E. Henderson, Theodore E. Whitmore, Kevin M. Klucher
-
Publication number: 20120042400Abstract: Novel polypeptides, designated RTD, which are capable of binding Apo-2 ligand are provided. Compositions including RTD chimeras, nucleic acid encoding RTD, and antibodies to RTD are also provided.Type: ApplicationFiled: November 29, 2010Publication date: February 16, 2012Applicant: GENENTECH, INC.Inventors: Avi J. Ashkenazi, Austin Gurney
-
Publication number: 20120040917Abstract: The present invention relates to compositions and methods for preparing splice variants of TNFalpha receptor (TNFR) in vivo or in vitro, and the resulting TNFR protein variants. Such variants may be prepared by controlling the splicing of pre-mRNA molecules and regulating protein expression with splice switching oligonucleotides or splice switching oligomers (SSOs). The preferred SSOs according to the invention target exon 7 or 8 of TNFR1 (TNFRSF1A) or TNFR2 (TNFRSF1A) pre-mRNA, typically resulting in the production of TNFR variants which comprise a deletion in part or the entire exon 7 or 8 respectfully. SSOs targeting exon 7 are found to result in a soluble form of the TNFR, which has therapeutic benefit for treatment of inflammatory diseases. The SSO's are characterized in that they are substantially incapable or incapable of recruiting RNaseH.Type: ApplicationFiled: December 3, 2010Publication date: February 16, 2012Inventors: HENRIK ØRUM, PETER L. SAZANI
-
Publication number: 20120015888Abstract: The invention provides T cell receptors (TCRs) having antigenic specificity for a cancer antigen, e.g., tyrosinase. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.Type: ApplicationFiled: January 25, 2010Publication date: January 19, 2012Inventors: Steven A. Rosenberg, Richard A. Morgan, Timothy L. Frankel, Peter Peng
-
Publication number: 20120015841Abstract: The invention relates to novel cells and cell lines, and methods for making and using them.Type: ApplicationFiled: February 1, 2010Publication date: January 19, 2012Applicant: CHROMOCELL CORPORATIONInventors: Kambiz Shekdar, Dennis Sawchuk, Purvi Manoj Shah
-
Publication number: 20110311530Abstract: The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered 0-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.Type: ApplicationFiled: August 19, 2011Publication date: December 22, 2011Inventors: Christine Ambrose, Jeffrey Thompson, Yen-Ming Hsu, Dingyi Wen, Yaping Sun
-
Patent number: 8076159Abstract: Briefly described, embodiments of this disclosure include ligand-regulable transactivation systems, methods of producing ligand-regulable transactivation systems, methods of using ligand-regulable transactivation systems, reporter polynucleotides, method of producing reporter polynucleotides, activator fusion proteins, methods of producing activator fusion proteins, methods of regulating gene expression in vitro and in vivo for gene therapy, methods of screening estrogen receptor modulators with therapeutic treatments (e.g., anticancer, antiosteoporosis, and hormone replacement treatments), method of screening compounds (e.g., drugs and environmental pollutants) for the estrogenic effect, methods of evaluating the estrogen receptor pathway under different pathological conditions are provided, and the like.Type: GrantFiled: February 10, 2010Date of Patent: December 13, 2011Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Sanjiv S. Gambhir, Ramasamy Paulmurugan
-
Patent number: 8021878Abstract: The present invention relates to a novel isolated leafhopper ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the leafhopper ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation system and methods for identifying molecules that modulate leafhopper ecdysone receptor activity.Type: GrantFiled: August 13, 2007Date of Patent: September 20, 2011Assignee: Intrexon CorporationInventor: Subba Reddy Palli
-
Patent number: 8003386Abstract: The present invention relates to novel Tumor Necorsis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6? & -6? proteins. TNFR-6? & -6? polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6? & -6? activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.Type: GrantFiled: January 13, 1998Date of Patent: August 23, 2011Assignee: Human Genome Sciences, Inc.Inventors: Reiner Gentz, Reinhard Ebner, Guo-Liang Yu, Steven M. Ruben, Jian Ni, Ping Feng
-
Patent number: 7964399Abstract: The present invention relates to the use of ligands for the FLK-1 receptor for the modulation of angiogenesis and vasculogenesis. The invention s based, in part, on the demonstration that Flk-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of Flk-1. These results indicate a major role for Flk-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express Flk-1 and the uses of expressed Flk-1 to evaluate and screen for drugs and analogs of VEGF involved in Flk-1 modulation by either agonist or antagonist activities is described. The invention also relates to the use of FLK-1 ligands, including VEGF agonists and antagonists, in the treatment of disorders, including cancer, by modulating vasculogenesis and angiogenesis.Type: GrantFiled: March 15, 2004Date of Patent: June 21, 2011Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Yissum Research, Development Company of the Hebrew University of JerusalemInventors: Axel Ullrich, Werner Risau, Birgit Millauer, Aviv Gazit, Alex Levitzki
-
Publication number: 20110111495Abstract: This invention discloses a kind of concentrated medium for large-scale culture of Chinese Hamster Ovary cell. The said medium comprises basic medium and high dose additives. This invention also discloses the method of adding the described concentrated medium in large-scale fed-batch culture of CHO cells.Type: ApplicationFiled: April 18, 2008Publication date: May 12, 2011Applicant: SHANGHAI CP GUOJIAN PHARMACEUTICAL CO. LTDInventors: Yajun Guo, Hao Wang, Geng Kou, Hui Hu, Sheng Hou, Min Tan
-
Publication number: 20110104167Abstract: A method of treating insulin resistance in a subject is provided. The method comprising administering to the subject a therapeutically effective amount of an agent capable of down-regulating phosphorylation of an IRS protein at at least one serine residue corresponding to amino acid 341, 412 and/or 413 of human IRS-1, thereby treating the insulin resistance in the subject. Also provided are methods and kits for diagnosing insulin resistance.Type: ApplicationFiled: October 30, 2005Publication date: May 5, 2011Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Yehiel Zick, Yanfang Liu, Denise Ronen
-
Patent number: 7928073Abstract: This invention relates to a purified polypeptide comprising an amino acid sequence chosen from the sequence SEQ ID NO:4 or biologically active amino acid sequences derived from SEQ ID NO:4.Type: GrantFiled: July 15, 2005Date of Patent: April 19, 2011Assignee: Sanofi-AventisInventors: Daniel Caput, Pascual Ferrara, Patrick Laurent, Natalio Vita
-
Patent number: 7892755Abstract: The present invention provides a method of screening a compound or its salt that alters binding properties of a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, and a ligand capable of specifically binding to the protein or its salt, which comprises using (a) the protein, its partial peptide, or a salt thereof and (b) the ligand; a screening kit therefor, and so on. The screening method and kit of the present invention are useful for screening an agent for the prevention/treatment of, e.g., digestive tract disorders, cancer, immune disorders, type II diabetes mellitus or obesity, etc.Type: GrantFiled: August 29, 2005Date of Patent: February 22, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Yasuaki Ito, Kazunori Nishi, Shoichi Ohkubo, Masataka Harada
-
Publication number: 20100330572Abstract: The present invention relates to a novel selection system for use in a eukaryotic cell culture process and for expression of a recombinant product of interest. The selection system is based on the introduction of an exogenous functional membrane-bound folate receptor gene together with the polynucleotide or gene encoding the product of interest into a eukaryotic cell and can be widely utilized with eukaryotic cells for which cellular viability is dependent upon folic acid uptake.Type: ApplicationFiled: December 19, 2008Publication date: December 30, 2010Inventors: Yehuda G. Assaraf, Thomas Jostock, Hans-Peter Knopf
-
Patent number: 7838288Abstract: The present invention relates to polypeptides capable of promoting odorant receptor cell surface localization and odorant receptor functional expression. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for odorant receptor accessory protein polymorphisms and mutations associated with disease states, as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins.Type: GrantFiled: October 30, 2008Date of Patent: November 23, 2010Assignee: Duke UniversityInventors: Hiroaki Matsunami, Momoka Matsunami, Harumi Saito, Hanyi Zhuang
-
Publication number: 20100279928Abstract: The invention relates to the use of the souluble LDL receptor (sLDLR) in viral hepatitis.Type: ApplicationFiled: January 7, 2009Publication date: November 4, 2010Inventor: Menachem RUBINSTEIN
-
Patent number: 7812126Abstract: Nucleic acids encoding mammalian, e.g., primate or rodent receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.Type: GrantFiled: March 4, 2008Date of Patent: October 12, 2010Assignee: Schering CorporationInventors: Christi L. Parham, Kevin W. Moore, Nicholas J. Murgolo, J. Fernando Bazan
-
Patent number: 7785834Abstract: The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist.Type: GrantFiled: May 1, 2007Date of Patent: August 31, 2010Assignees: Ercole Biotech, Inc., University of North Carolina at Chapel Hill, Santaris Pharma A/SInventors: Peter L. Sazani, Maria Graziewicz, Ryszard Kole, Henrik Ørum
-
Patent number: 7776590Abstract: A stable eukaryotic cell line that expresses hERG and exhibits a stable current under electrophysiological test conditions is provided.Type: GrantFiled: December 11, 2006Date of Patent: August 17, 2010Assignee: Roche Palo Alto LLCInventors: Paul Shartzer Dietrich, Bruce Koch, Heather Guthrie, Ulrich Andreas Gubler
-
Publication number: 20100178672Abstract: The current invention comprises a CHO cell which is expressing a constitutively active mitogenic receptor, a method of obtaining such a CHO cell, and a method for the expression of a heterologous polypeptide using a CHO cell according to the invention.Type: ApplicationFiled: June 25, 2008Publication date: July 15, 2010Inventors: Robert DeLange, Erhard Kopetzki
-
Publication number: 20100120068Abstract: A modified G-protein-coupled receptor (GPCR), having modified ligand affinity is provided by binding a G-protein-coupled receptor to a polypeptide consisting of an amino acid sequence of SEQ ID NO: 1. Furthermore, agonists for or antagonists against the modified GPCR are screened using a transformant in which the modified GPCR has been expressed. This makes it possible to provide a technique for analyzing the function of many putative GPCRs whose entities have not been clarified.Type: ApplicationFiled: May 22, 2008Publication date: May 13, 2010Applicant: Pharmacome LLCInventor: Ikunobu Muramatsu
-
Patent number: 7691628Abstract: The present invention relates to the use of receptors of the Rev-erb family to screen substances which are useful in the treatment of lipid metabolism dysfunctions associated with apolipoprotein C-III. The invention relates more particularly to screening methods for selecting substances which are useful for the treatment of these dysfunctions. Lastly, the invention relates to the use of the substances thus identified for the preparation of therapeutic compositions which are useful for the treatment of lipid metabolism dysfunctions associated with apolipoprotein C-III. The subject of the present invention is also the use of screening tests for the characterization, justification and claim of the mechanism of action of substances possessing anti-atherosclerotic properties using the Rev-erb receptors and/or the response elements thereof, as well as their effect on apo C-III.Type: GrantFiled: June 21, 1999Date of Patent: April 6, 2010Assignee: Merck Patent GmbHInventors: Eric Raspe, Yves Bonhomme
-
Patent number: 7618818Abstract: The present invention relates to a method for detecting leptin receptor ligands by measuring the energy transfer between fusion proteins comprising a leptin receptor and an energy donor protein or an energy acceptor acceptor protein proteins. The present invention also relates to fusion proteins for implementing said method.Type: GrantFiled: April 9, 2007Date of Patent: November 17, 2009Assignees: Aventis Pharma S.A., Institut de la Sante et de la Recherche Medicale Scientifique, Centre National de la RechercheInventors: Ralf Jockers, Cyril Couturier
-
Patent number: 7563586Abstract: The present invention provides a method of identifying a modulator of a voltage gated sodium channel (VGSC), which method comprises bringing into contact a VGSC, a p11 peptide and a test compound under conditions where the VGSC and the p11 peptide are capable of forming a complex in the absence of the test compound; and measuring an activity of the VGSC, wherein a change in the activity of the VGSC relative to the activity in the absence of the test compound indicates that the test compound is a modulator of said VGSC. Compounds identified in such screening methods are proposed for use in the treatment of VGSC-related conditions, for example in the treatment or prevention of pain. Also provided are methods of enhancing the functional expression of a voltage gated sodium channel (VGSC) in a cell comprising the step of increasing the level of p11 in the cell.Type: GrantFiled: August 20, 2002Date of Patent: July 21, 2009Assignee: University College LondonInventors: Kenji Okuse, Mark Baker, Louisa Poon, John Nicholas Wood, Misbah Malik-Hall
-
Publication number: 20090124005Abstract: Expression-enhancing nucleotide sequences for expression in eukaryotic systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Enhanced expression and stability regions (EESYRs) are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.Type: ApplicationFiled: June 4, 2008Publication date: May 14, 2009Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Gang CHEN, Robert Babb, James P. Fandl
-
Patent number: 7491503Abstract: The invention is directed to a method for identifying substances acting as ligands for transfected receptors by using transfected markers to measure receptor/ligand interactions. The present invention also relates to a method of identifying compounds which act as inverse agonists of the 5-HT2A receptor, the method comprising contacting a constitutively active 5-HT2A receptor with at least one test compound and determining any decrease in the amount of basal activity of the receptor so as to identify a test compound which is an inverse agonist of the 5-HT2A receptor. Such inverse agonists may be used in the treatment of schizophrenia and related psychoses.Type: GrantFiled: May 3, 2006Date of Patent: February 17, 2009Assignee: Acadia Pharmaceuticals, Inc.Inventor: Mark R. Brann
-
Publication number: 20090042199Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human spleen (Hyseq clone identification numbers 2938352 (SEQ ID NO: 1)). Other aspects of the invention include vectors containing processes for producing novel human secreted CD84-like polypeptides, and antibodies specific for such polypeptides.Type: ApplicationFiled: April 10, 2008Publication date: February 12, 2009Applicant: NUVELO, INC.Inventors: Chiaoyun Kuo, Bryan J. Boyle, Jian-Rui Wang, Y. Tom Tang, Chenghua Liu, Radoje T. Drmanac
-
Publication number: 20090017537Abstract: Functional assays that detect the effect of a particular compound or compounds on the activation of at least one human T2R polypeptide are provided. These assays include e.g., assays which detect the effect of said compound on intracellular calcium, second messengers such as cAMP, cGMP, current e.g., by use of voltage-clamp or patch-clamp, techniques, fluorescence polarization or FRET assays, and the like. These assays are useful in identifying compounds that putatively elicit or modulate (inhibit or enhance) bitter taste in human subjects, e.g. bitter taste blockers. The effect of identified compounds on taste may be further evaluated in human or animal taste tests.Type: ApplicationFiled: June 4, 2008Publication date: January 15, 2009Inventor: Jon Elliot Adler
-
Publication number: 20080262087Abstract: The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. Also the present invention relates to the use of hetero-oligomeric taste receptors comprising T1R1/T1R3 and T1R2/T1R3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet taste stimuli. Further, the invention relates to the constitutive of cell lines that stably or transiently co-express a combination of T1R1 and T1R3; or T1R2 and T1R3; under constitutive or inducible conditions.Type: ApplicationFiled: October 31, 2007Publication date: October 23, 2008Applicant: Senomyx, Inc.Inventors: Mark Zoller, Xiaodong Li, Lena Staszewski, Shawn O'Connell, Sergey Zozulya, Jon Elliot Adler, Hong Xu, Fernando Echeverri
-
Patent number: 7435808Abstract: The present invention provides novel polynucleotides encoding human AdipoR2v1 polypeptides, mouse AdipoR2v1 polypeptides, human AdipoR3 polypeptides, human AdipoR2v2 polypeptides, human AdipoR3v1 polypeptides, rat AdipoR1 polypeptides, rat AdipoR2 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human AdipoR2v1 polypeptides, mouse AdipoR2v1 polypeptides, human AdipoR3 polypeptides, human AdipoR2v2 polypeptides, human AdipoR3v1 polypeptides, rat AdipoR1 polypeptides, rat AdipoR2 polypeptides, to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.Type: GrantFiled: June 23, 2004Date of Patent: October 14, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Shujian Wu, Ning Lee, Dong Cheng
-
Publication number: 20080244761Abstract: The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. Also the present invention relates to the use of hetero-oligomeric taste receptors comprising T1R1/T1R3 and T1R2/T1R3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet taste stimuli. Further, the invention relates to the constitutive of cell lines that stably or transiently co-express a combination of T1R1 and T1R3; or T1R2 and T1R3; under constitutive or inducible conditions.Type: ApplicationFiled: October 31, 2007Publication date: October 2, 2008Applicant: Senomyx, Inc.Inventors: Mark Zoller, Xiaodong Li, Lena Staszewski, Shawn O'Connell, Sergey Zozulya, Jon Elliot Adler, Hong Xu, Fernando Echeverri
-
Patent number: 7425445Abstract: The present invention relates to polypeptides capable of promoting odorant receptor cell surface localization and odorant receptor functional expression. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for odorant receptor accessory protein polymorphisms and mutations associated with disease states, as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins.Type: GrantFiled: June 20, 2005Date of Patent: September 16, 2008Assignee: Duke UniversityInventors: Hiroaki Matsunami, Momoka Matsunami, Harumi Saito, Hanyi Zhuang
-
Patent number: 7416848Abstract: This invention provides isolated nucleic acids encoding mammalian SNORF25 receptors, purified mammalian SNORF25 receptors, vectors comprising nucleic acid encoding mammalian SNORF25 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF25 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF25 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF25 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF25 receptors, methods of isolating mammalian SNORF25 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF25 receptors, as well as methods of determining binding of compounds to mammalian SNORF25 receptors, methods of identifying agonists and antagonists of SNORF25 receptors, and agonists and antagonists so identified.Type: GrantFiled: October 22, 2002Date of Patent: August 26, 2008Assignee: H. Lundbeck A/SInventors: James A. Bonini, Beth E. Borowsky, Nika Adham, Noel Boyle, Thelma O. Thompson
-
Patent number: 7405051Abstract: A screening tool for an antiplatelet agent wherein the tool is a human ADP receptor P2TAC protein, a variation functionally equivalent thereto, or a homologous protein thereof, and a screening tool for an antiplatelet agent wherein the tool is a transformant which is transformed with an expression vector comprising a DNA encoding the protein and is expressing the polypeptide are disclosed. Further, a method for detecting an ADP receptor P2TAC ligand, antagonist, or agonist by using the screening tool for an antiplatelet agent, and a method for screening an antiplatelet agent by the detecting method are disclosed.Type: GrantFiled: October 31, 2001Date of Patent: July 29, 2008Assignee: Astellas Pharma Inc.Inventors: Jun Takasaki, Mitsuyuki Matsumoto, Masazumi Kamohara, Tetsu Saito, Takahide Ohishi, Takatoshi Soga
-
Patent number: 7393945Abstract: An estrogen receptor gene and utilization of the estrogen gene are described. The estrogen receptor gene has a nucleotide sequence coding for any of the following amino acid sequences: (a) the amino acid sequence of SEQ ID NO: 1, (b) the amino acid sequence of SEQ ID NO: 4, (c) an amino acid sequence exhibiting 95% or more amino acid identity to the amino acid sequence of SEQ ID NO: 1, and (d) an amino acid sequence exhibiting 95% or more amino acid identity to the amino acid sequence of SEQ ID NO: 4.Type: GrantFiled: July 23, 2002Date of Patent: July 1, 2008Assignee: Sumitomo Chemical Company LimitedInventor: Koichi Saito
-
Patent number: 7393655Abstract: This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.Type: GrantFiled: April 15, 2004Date of Patent: July 1, 2008Assignee: H. Lundbeck A/SInventors: John A. Salon, Thomas M. Laz, Raisa Nagorny, Amy F. Wilson
-
Patent number: 7381560Abstract: Disclosed are immunologically active antibodies directed against the CD20 antigen, as well as host cells comprising nucleic acid sequences encoding the light chains and heavy chains of immunologically active antibodies wherein the cell is capable of expressing and secreting an immunologically active chimeric anti-CD20 antibody and methods of using such host cells to make purified antibodies. The antibodies are useful for treating and diagnosing B cell disorders.Type: GrantFiled: July 25, 2001Date of Patent: June 3, 2008Assignee: Biogen Idec Inc.Inventors: Darrell R. Anderson, Nabil Hanna, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
-
Patent number: 7368285Abstract: The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. Also the present invention relates to the use of hetero-oligomeric taste receptors comprising T1R1/T1R3 and T1R2/T1R3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet taste stimuli. Further, the invention relates to the constitutive of cell lines that stably or transiently co-express a combination of T1R1 and T1R3; or T1R2 and T1R3; under constitutive or inducible conditions.Type: GrantFiled: June 26, 2002Date of Patent: May 6, 2008Assignee: Senomyx, Inc.Inventors: Mark Zoller, Xiaodong Li, Lena Staszewski, Shawn O'Connell, Sergey Zozulya, Jon Elliot Adler, Hong Xu, Fernando Echeverri
-
Patent number: 7306922Abstract: A novel gene PGC-3, and its role in regulating the transcriptional activity of PPAR? in adipose tissue. PGC-3 is highly expressed in human white adipose tissue and has utility in the development of new therapeutic agents for use in the treatment of obesity and other related disorders such as non-insulin dependent diabetes mellitus, insulin resistance syndrome, dyslipidemia, and atherosclerosis.Type: GrantFiled: September 12, 2001Date of Patent: December 11, 2007Assignee: AstraZeneca ABInventors: Kevin Anthony Hart, Carl Thomas Montague, Antonio Vidal-Puig
-
Patent number: 7285413Abstract: A tool for the isolation of c-kit expressing cells is provided. This tool consists of a c-kit plasmid targeting vector which is capable of integrating into the wild type c-kit allele and encodes a chimeric fluorescent protein comprising a nucleolar localization signal such as, TCOF-12, RLP313, RPS254 or Fxr2h5. The construct generates a condensed, bright, fluorescent signal that can be localized in living tissue and after dissociation. The construct allows visualization using confocal microscopy and allows automated cell sorting of the dissociated cells using amongst others flow cytometry.Type: GrantFiled: December 12, 2002Date of Patent: October 23, 2007Assignee: Janssen Pharmaceutica N.V.Inventors: Mira Maria Willy Wouters, Karine Alfonsine Astrid Smans, Jean-Marie Vanderwinden
-
Patent number: 7282483Abstract: The present invention provides DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: July 3, 2001Date of Patent: October 16, 2007Assignee: Amgen Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 7238776Abstract: The present invention provides DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: July 3, 2001Date of Patent: July 3, 2007Assignee: Amgen Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 7211259Abstract: Novel 4-1BB ligand (4-1BB-L) polypeptides and a human cell surface receptor designated 4-1BB that binds 4-1BB-L are provided. Isolated 4-1BB-L-encoding and human 4-1BB-encoding DNA sequences, recombinant expression vectors comprising the isolated DNA sequences, and host cells transformed with the recombinant expression vectors are disclosed, along with methods for producing the novel polypeptides by cultivating such transformed host cells. Soluble forms of the 4-1BB-L or 4-1BB polypeptides are derived from the extracellular domains thereof.Type: GrantFiled: August 5, 1997Date of Patent: May 1, 2007Assignee: Immunex CorporationInventors: Raymond G. Goodwin, Craig A. Smith
-
Patent number: 7198913Abstract: The present invention is directed to novel polypeptides having homology to members of the tumor necrosis factor receptor family and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: September 12, 2002Date of Patent: April 3, 2007Assignee: Genentech, Inc.Inventors: Audrey Goddard, James Pan, Minhong Yan
-
Patent number: 7166445Abstract: The invention provides improved methods of recombinant protein production in cell culture. More specifically, the invention relates to the modulation of the IGF-1 signaling pathway in cells so as to improve production characteristics.Type: GrantFiled: February 28, 2005Date of Patent: January 23, 2007Assignee: Immunex CorporationInventors: Arvia E. Morris, Pranhitha Reddy
-
Patent number: 7157244Abstract: The present invention provides an isolated mammalian adenosine receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by adenosine. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian adenosine receptor.Type: GrantFiled: January 17, 2001Date of Patent: January 2, 2007Assignee: Schering CorporationInventors: Joseph A. Hedrick, Jean E. Lachowicz, Wei Wang, Eric L. Gustafson
-
Nucleic acids encoding BAFF receptor, chimeric proteins and methods and compositions related thereto
Patent number: 7112421Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.Type: GrantFiled: September 6, 2001Date of Patent: September 26, 2006Assignee: Biogen Idec MA Inc.Inventors: Christine M. Ambrose, Jeffrey S. Thompson -
Patent number: RE39792Abstract: A biochemically defined culture medium for culturing engineered Chinese hamster ovary (CHO) cell lines, which is essentially free from protein, lipid and carbohydrate isolated from an animal source, having water, an osmolality regulator, a buffer, an energy source, amino acids including L-glutamine, an inorganic or recombinant iron source, and a synthetic or recombinant growth factor, and optionally non-ferrous metal ions vitamins and cofactors. Also cells adapted to grow in such a culture medium. REEXAMINATION RESULTS The questions raised in reexamination request no. 90/006656, filed Jun. 2, 2003 have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e), for ex parte reexaminations, or the reexamination certificate required by 35 U.S.C. 316 as provided in 37 CFR 1.997(e) for inter partes reexaminations.Type: GrantFiled: November 22, 2004Date of Patent: August 21, 2007Assignee: SmithKline Beecham CorporationInventors: Michael J. Keen, Nicholas T. Rapson